Topiramate NDC 70748-277

NDC codes

FDA NDC Directory

Product NDC (as listed)70748-277Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70748-0277Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70748-277-06	70748027706	30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (70748-277-06)Marketed from Feb 3, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Topiramate
Generic name (nonproprietary): topiramate
Active ingredients: Topiramate — 100 mg/1
Dosage form: Capsule, Extended release
Route: Oral
Labeler: Lupin Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215561
Marketing start: Feb 3, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 2C19 Inhibitors (Mechanism)Cytochrome P450 3A4 Inducers (Mechanism)Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 70748-277_68180c67-ab30-49d0-aece-5a8d476097e2SPL ID 68180c67-ab30-49d0-aece-5a8d476097e2SPL set ID e310afcd-1260-434e-a994-34549c789d99RxCUI 1436239, 1437278, 1437283, 1437288UNII 0H73WJJ391

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470748027706 followed by a unit qualifier and the quantity

Package 70748-0277-06. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 30, 2026.

Indications (excerpt from the label)

Topiramate extended-release capsules USP are indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 6 years of age and older ( 1.1 ); adjunctive therapy for the treatment of partial-onset, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome (LGS) in patients 6 years of age and older ( 1.2 ) Preventive treatment of migraine in patients 12 years of age and older ( 1.3 ) 1.1 Monotherapy Epilepsy Topiramate extended-release capsules USP are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 6 years o…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 215561

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 215561
Product	Strength	Form · route	Labeler	Product NDC
Topiramate	Topiramate 25 mg/1	Capsule, Extended releaseOral	Lupin Pharmaceuticals, Inc.	70748-275
Topiramate	Topiramate 50 mg/1	Capsule, Extended releaseOral	Lupin Pharmaceuticals, Inc.	70748-276
Topiramate	Topiramate 200 mg/1	Capsule, Extended releaseOral	Lupin Pharmaceuticals, Inc.	70748-278